Table 2.
Clinical trials of MDM2 inhibitors combined with immunotherapy.
| NCT Number | Diseases | Phase | Intervention 1 | Intervention 2 | Population | Status |
|---|---|---|---|---|---|---|
| NCT03787602 | Merkel Cell Carcinoma | 1,2 | Navtemadlin (KRT-232) | Navtemadlin + Avelumab(anti PD-L1) | Enrollment:115 Age:18 Years and older Sex:All |
Recruiting |
| NCT05705466 | Non Small Cell Lung Cancer | 1,2 | Navtemadlin + Pembrolizumab(anti PD-1) | Navtemadlin placebo + Pembrolizumab | Enrollment:92 Age:18 Years and older Sex:All |
Not yet recruiting |
| NCT03964233 | Solid Tumors | 1,2 | Dose Escalation/Expansion-BI 907828 +Ezabenlimab(anti PD-1) |
Dose Escalation-BI 907828 + Ezabenlimab + BI 754111(anti LAG-3) | Enrollment:140 Age:18 Years and older Sex:All |
Recruiting |
| NCT03940352 | Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome |
1 | Siremadlin(HDM201)+ MBG453(anti TIM-3) |
Siremadlin + Venetoclax | Enrollment:52 Age:18 Years and older Sex:All |
Active, not recruiting |
| NCT03555149 | Colorectal Cancer | 1,2 | Idasanutlin(RG7338)+ Atezolizumab(anti PD-L1) |
Atezolizumab + other treatment (Imprime PGG + Bevacizumab, Isatuximab, Selicrelumab + Bevacizumab, Regorafenib, Regorafenib + AB928, LOAd703) | Enrollment:96 Age:18 Years and older Sex:All |
Terminated |
| NCT03566485 | Stage III and IV (ER+) Breast Cancer | 1,2 | Idasanutlin(RG7338) + Atezolizumab | – | Enrollment:12 Age:18 Years and older Sex:Female |
Terminated |
| NCT04785196 | Liposarcoma, Advanced Solid Tumor |
1,2 | Alrizomadlin(APG-115)+ Toripalimab(anti PD-1) |
– | Enrollment:95 Age:18 Years and older Sex:All |
Recruiting |
| NCT03611868 | Unresectable or Metastatic Melanoma, Advanced Solid Tumors |
1,2 | Alrizomadlin(APG-115)+ Pembrolizumab | – | Enrollment:140 Age:12 Years and older Sex:All |
Recruiting |
| NCT05447663 | Acute Myeloid Leukemia | 1,2 | Siremadlin(HDM201) + Donor Lymphocyte Infusion | – | Enrollment:38 Age:18 Years and older Sex:All |
Recruiting |